Piercey O, Chantrill L, Hsu H, Ma B, Price T, Tan IB, Teng H, Tie J, Desai J. Expert consensus on the optimal management of BRAFV600E‐mutant metastatic colorectal cancer in the Asia‐Pacific region. Asia-Pacific Journal of Clinical Oncology. 2025;21(1):10.1111/ajco.14132
Hitchen N, Shahnam A, Tie J. Circulating Tumor DNA: A Pan-Cancer Biomarker in Solid Tumors with Prognostic and Predictive Value. Annual Review of Medicine. 2025;76(1):10.1146/annurev-med-100223-090016
Loft M, Wong V, Kosmider S, Wong R, Shapiro J, Hong W, Jennens R, Tie J, Caird S, Steel S, Lee B, Nott L, Khattak MA, Lim S, Chong G, Hayes T, Underhill C, McLachlan S, Rainey N, Dunn C, Gibbs P. Real‐world impact of pembrolizumab availability for deficient mismatch repair metastatic colorectal cancer. Internal Medicine Journal. 2025;55(1):10.1111/imj.16575
Burge ME, Espinoza D, Sjoquist KM, Siu DH, Mercieca-Bebber R, Chantrill LA, Karapetis CS, Steer CB, Yip S, Cuff J, Winata S, Tie J, Thaker DA, Srivastav R, Abdi E, Strickland A, Segelov E, Francesconi A, Price T, Ladwa R, Joubert W, Tebbutt NC. AGITG MONARCC: A randomized phase 2 study of panitumumab monotherapy and panitumumab plus 5-Fluorouracil as first-line therapy for older patients with RAS and BRAF wild type metastatic colorectal cancer. A study by the Australasian Gastro-Intestinal Trials Group (AGITG). Clinical Colorectal Cancer. 2024;:10.1016/j.clcc.2024.11.003
Muhandiramge J, Zalcberg JR, Warner ET, Polekhina G, Gibbs P, van Londen GJ, Bernstein WB, Macrae F, Haydon A, Tie J, Millar JL, Mar VJ, Gately L, Tonkin A, Ford L, Umar A, Chan AT, Woods RL, Orchard SG. Cardiovascular disease and stroke following cancer and cancer treatment in older adults. Cancer. 2024;130(23):10.1002/cncr.35503
Glewis S, Lingaratnam S, Lee B, Campbell I, IJzerman M, Fagery M, Harris S, Georgiou C, Underhill C, Warren M, Campbell R, Jayawardana M, Silva SSM, Martin JH, Tie J, Alexander M, Michael M. Pharmacogenetic‐guided dosing for fluoropyrimidine (DPYD) and irinotecan (UGT1A1*28) chemotherapies for patients with cancer (PACIFIC‐PGx): A multicenter clinical trial. Clinical and Translational Science. 2024;17(12):10.1111/cts.70083
Tie J. Abstract IA017: ctDNA based detection of MRD in colon cancer: Towards clinical implementation. Clinical Cancer Research. 2024;30(21_Supplement):10.1158/1557-3265.liqbiop24-ia017
Allan Z, Wang Y, Tie J, Tebbutt N, Clemons N, Papadopoulos N, Kinzler K, Vogelstein B, Liu DS. Abstract A049: Peritoneal tumor DNA as a prognostic biomarker in locally advanced gastroesophageal cancer: A pilot prospective cohort study. Clinical Cancer Research. 2024;30(21_Supplement):10.1158/1557-3265.liqbiop24-a049
Kim GY, Jalali A, Gard G, Yeung JM, Chau H, Gately L, Houli N, Jones IT, Kosmider S, Lee B, Lee M, Nott L, Shapiro JD, Tie J, Thomson B, To YH, Wong V, Wong R, Dunn C, Johns J, Gibbs P. Initial assessment of resectability of colorectal cancer liver metastases versus clinical outcome. Clinical Colorectal Cancer. 2024;:10.1016/j.clcc.2024.10.001
Segal NH, Tie J, Kopetz S, Ducreux M, Chen E, Dienstmann R, Hollebecque A, Reilley MJ, Elez E, Cosaert J, Cain J, Soo-Hoo Y, Hewson N, Cooper ZA, Kumar R, Tabernero J. COLUMBIA-1: a randomised study of durvalumab plus oleclumab in combination with chemotherapy and bevacizumab in metastatic microsatellite-stable colorectal cancer. British Journal of Cancer. 2024;131(6):10.1038/s41416-024-02796-3
